Skip to content
Screener

Neuropace, Inc. NPCE Operating Income

Operating Income at other companies

Medtronic logo
MedtronicMDT
$1.87B+30.4%
LivaNova logo
LivaNovaLIVN
$49.48M-8.7%
ClearPoint Neuro logo
ClearPoint NeuroCLPT
-$8.48M-37.6%
Rapport Therapeutics, Inc. logo
Rapport Therapeutics, Inc.RAPP
-$60.81M-106%
Inspire Medical Systems logo
Inspire Medical SystemsINSP
-$1.12M+24.7%
CVRx, Inc. logo
CVRx, Inc.CVRX
-$13.02M+9.4%

Other financials

Income statement

See full
Revenue$22.8M+17.1%
Gross profit$18.9M+16.6%
Net income-$6.2M+28.3%
EPS (diluted)-$0.18+30.8%

Balance sheet

See full
Cash & equivalents$12.8M-44.4%
Total debt$69.9M-2.2%
Total equity$11.9M-38.9%
Total assets$97.0M-8.6%

Cash flow

See full
Operating cash flow-$3.9M-87.1%
CapEx$125.0K-25.6%
Free cash flow-$4.0M-78.7%

Valuation

See full
Market cap$505.61M+73.4%
Enterprise value$562.76M+65.5%
P/S5.1×+1.7×

Profitability

See full
Gross margin79.6%+2.6pp
Operating margin-15.3%-4.3pp
Net margin-19.3%-5.2pp
FCF margin-12.2%-3.3pp

Returns & leverage

See full
Return on equity-122.1%-28.9pp
Debt / equity5.9×+2.2×
Current ratio4.9×-0.5×

Where this comes from

Reported directly by Neuropace, Inc. in its filing.

Tagged under the XBRL concept us-gaap:OperatingIncomeLoss.

The source filing: Neuropace, Inc.’s 10-Q, filed August 11, 2026.

Filed
Aug 11, 2026, 4:33 PM EDT
Fiscal quarter
Q4 FY2030
Calendar quarter
Q4 2030
Accession
0001528287-26-000030
(in thousands, except for share and per share amounts)Three Months Ended June 30, 2026Three Months Ended June 30, 2025Six Months Ended June 30, 2026Six Months Ended June 30, 2025
Research and development6,8986,84514,08714,285
General and administrative5,0276,0689,87110,114
Total operating expenses24,04924,40247,66546,293
Loss from continuing operations(5,143)(8,189)(10,748)(14,949)
Interest income5237181,0881,511
Interest expense(1,539)(2,059)(3,060)(4,212)
Other income (expense), net(41)(486)(206)(568)
Net loss and comprehensive loss from continuing operations(6,200)(10,016)(12,926)(18,218)

Item 1. Financial Statements (Unaudited)

FAQ

What is Neuropace, Inc.'s operating income?
Neuropace, Inc. (NPCE) reported operating income of -$5.14M in Q2 2026.
How has Neuropace, Inc.'s operating income changed year-over-year?
Neuropace, Inc.'s operating income increased by 37.2% year-over-year, from -$8.19M to -$5.14M.
What is the long-term trend for Neuropace, Inc.'s operating income?
Over 4 years (2021 to 2025), Neuropace, Inc.'s operating income has grown at a -7.1% compound annual growth rate (CAGR), from -$23.74M to -$17.7M.
What does operating income mean?
Gross profit minus all operating expenses (SG&A, R&D, D&A). Measures the profit from core business operations before interest, taxes, and non-operating items.

Ask your AI about Neuropace, Inc.'s operating income.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude